UpdatesPress Release
Wockhardt reported a positive Q4 PBT of ₹189 Cr and full-year PBT of ₹238 Cr.
Wockhardt LimitedWOCKPHARMA · Filed with the exchange
Q4 revenue grew 30% to ₹965 Cr, while full-year revenue hit ₹3,373 Cr.
Biotech operations soared 126% in Q4. Novel antibiotic Zaynich progressed with EMA accelerated assessment, and Miqnaf launched in India.
No comments yet. Be the first.